MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Dec. 19, 2005--Asthmatx, Inc., a medical device company that has developed an investigational outpatient procedure for the treatment of asthma, announced today it has completed the sale of $27 million of Series C preferred stock. Vanguard Ventures and HBM BioCapital co-led the oversubscribed financing, with the majority of capital coming from existing investors including Polaris Venture Partners, MedVenture Associates, and Montreux Equity Partners.
